CIPH Ciphergen Biosystems (MM)

Ciphergen and UCL Will Utilize Clinical Samples Collected in Large Scale Studies of Ovarian Cancer FREMONT, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that it has signed a research and license agreement with UCL (University College London) and UCL BioMedica Plc. to utilize Ciphergen's suite of proteomic solutions (Deep Proteome(TM), Pattern Track(TM) Process, and ProteinChip(R) System) to further their ongoing research in ovarian cancer. The principal investigator, Professor Ian Jacobs of UCL and President of the European Society of Gynecological Oncology (ESGO), is recognized as a world authority on ovarian cancer. He and his team manage the largest screening trial in the world -- the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) which involves 200,000 women. Ciphergen and its collaborators at UCL will work together to further validate and characterize ovarian cancer biomarkers as well as discover potential new biomarkers. They plan to utilize samples from a new prospective collection of over 1000 patients with ovarian cancer, benign neoplasms and 4000 healthy controls recruited through 10 UK centres. This work is expected to address multiple clinical questions, including validation of markers described in Cancer Research in August 2004, and the discovery of additional biomarkers that distinguish ovarian cancer from other gynecologic masses. Under the terms of the agreement, Ciphergen will have exclusive rights to license discoveries made during the course of this collaboration. "We are very excited to be working with Ciphergen. It is our belief that this technology could lead to breakthrough discoveries in the area of women's health. Combining Ciphergen's expertise in translational proteomics with our clinical resources and research expertise is an important step in our efforts to accelerate the development of new diagnostic approaches to ovarian and breast cancer" said Professor Ian Jacobs. "Ciphergen is delighted to announce this agreement with University College London, a world renowned center of excellence for research into women's health. Professor Ian Jacobs is a leading authority in the field and by joining forces with Professor Jacobs and his team, we are hopeful that our joint efforts will translate into improved diagnosis and treatment of these major life-threatening diseases," said Gail Page, President and Chief Operating Officer of Ciphergen. About Ciphergen Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. About UCL (University College London) Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. About UCL BioMedica Plc. UCL BioMedica Plc (a wholly owned subsidiary of University College London) aims to generate income and create capital value for UCL through the commercial exploitation of the bioscience research base at UCL and its associated Institutes. Additional information about UCL BioMedica Plc can be found at http://www.uclbiomedica.com/ Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the validation of biomarkers described in Cancer Research in August 2004 and discovery of additional biomarkers that distinguish ovarian cancer from other gynecological masses, the development of new diagnostic approaches to ovarian and breast cancer, and future publications describing the utility of ovarian cancer biomarkers. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the possibility that the biomarker assay described in Cancer Research or any other biomarker panel discovered by Ciphergen may fail to validate in larger studies as providing an accurate diagnostic for ovarian and/or breast cancer, the ProteinChip technology's ability to validate and/or develop protein biomarkers as novel drug targets, diagnostic or toxicology assays, and the Company's ability to successfully commercialize such tests. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated August 9, 2005, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip, and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297 Web site: http://www.uclbiomedica.com/ Web site: http://www.ciphergen.com/

Copyright